AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02182011
Drug: Streptokinase
RxNorm normalized name: Streptokinase
DrugBank: Streptokinase (DB00086)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04529772
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Investigational Product
Trial: NCT04529772
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Investigational Product
Trial: NCT04529772
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Investigational Product
Trial: NCT00305825
Drug: letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00285207
Drug: A007
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 days of 28 day cycle
Trial: NCT01334242
Drug: Schedule E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Split dose, dosing 1 hour before breakfast and dinner
Trial: NCT02789579
Drug: levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: There are 50 patients in the group,each patient receives levofloxacin 0.5g, qd, po 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
Trial: NCT02789579
Drug: Nitrofurantoin
RxNorm normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: There are 50 patients in the group,each patient receives nitrofurantoin 0.1g, qd, po 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
Trial: NCT03768882
Drug: paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000 mg of paracetamol (parol 10mg/ml Mefar, Turkey) intravenous (IV) was given 102 patients
Trial: NCT02789579
Drug: cefuroxime
RxNorm normalized name: Cefuroxime
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: There are 150 patients in the group, 30 minutes before surgery, each patient is given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
Trial: NCT03768882
Drug: Dexketoprofen
RxNorm normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second group: dexketoprofen 50 MG (Arveles ampoule -İE Ulagay -Menarini,Turkey) intravenous (IV) was given 98 patients
Trial: NCT01985854
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01985854
Drug: Desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01097876
Drug: PF-04447943 25 mg
RxNorm normalized name: timolol
DrugBank: PF-04447943 (DB11953)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25 mg PF-04447943 BID for 7 days (period 1) 7 day washout (no drug) 7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2) 7 days of 10 mg donepezil QD and 25 mg PF-04447943 BID (Period 3)
Trial: NCT02749123
Drug: lidocaine 5% patch
RxNorm normalized name: LIDOCAINE 5% PATCH
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10cmx 14 cm transdermal patch sealed in its own pouch
Trial: NCT02749123
Drug: lidocaine 3.6%, menthol 1.25%
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10cmx 14 cm transdermal patch sealed in its own pouch
Trial: NCT05969327
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral supplementation of two different doses
Trial: NCT06087003
Drug: Basiliximab Injection
RxNorm normalized name: basiliximab Injection
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: As an induction treatment for kidney transplantation
Trial: NCT06087003
Drug: rabbit ATG
RxNorm normalized name: Rabbit ATG
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As an induction treatment for kidney transplantation
Trial: NCT02983227
Drug: GDC-0853
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GDC-0853 was administered orally at a dose of 200mg, as per the dosing schedules described above.
Trial: NCT00837031
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The starting dose of lenalidomide for the lead-in portion will be 25 mg orally daily on Days 1-21, followed by a 7-day rest period (28-day cycle). If the 25-mg dose of lenalidomide is found to be intolerable or unsafe (i.e., if more than one of the 6 patients experience a DLT), then the dose will be reduced to 20 mg orally daily, and 6 additional patients will be treated. All patients will receive lenalidomide at the confirmed tolerable dose (either 25 mg or 20 mg given orally daily on Days 1-21 of a 28-day cycle) until disease progression. If the 20-mg daily dose is found to be intolerable or unsafe, enrollment will be put on hold.
Trial: NCT01887301
Drug: Sativex
RxNorm normalized name: Castanea sative leaf extract
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive four sprays (each 100 uL) of Sativex to the oral mucosa, which contain 10.8 mg THC and 10 mg CBD in total.
Trial: NCT02935374
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The children with acute otitis media will be treated with amoxixillin mixture, 100mg/ml, 40mg/kg/d, divided to two daily doses for 7 days.
Trial: NCT02935374
Drug: Amoxicillin-Potassium Clavulanate
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The children with acute otitis media will be treated with amoxixillin-clavulanate mixture, 80mg/ml, 45mg/kg/d, divided to two daily doses for 7 days.
Trial: NCT04263051
Drug: UCPVax + Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: UCPVax will be administrated at day 1 of week 1 ; 2 ; 3 ; 5 ; 6 ; 7 and then week 13 and every 2 months until months 12.~Nivolumab will be administrated at the dose of 480 mg at day 1 and then every 4 weeks until disease progression or unacceptable toxicity according to label.~At the end of COMBO phase, nivolumab will be continued every 4 weeks for maximum 24 months from the first administration, until disease progression or unacceptable toxicity according to standard of care.
Trial: NCT06165146
Drug: Repaglinide
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06165146
Drug: Pirtobrutinib
RxNorm normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT00957385
Drug: Revlimid
RxNorm normalized name: Revlimid
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10mgs PO daily for 21 days of each 28 day cycle. Number of cycles: total of 24 or until subject relapses or unacceptable toxicity develops.
Trial: NCT00837031
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000 mg/m2 IV will be administered on Days 1, 8, and 15 for a 28-day cycle.
Trial: NCT03179501
Drug: NP001
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: NP001
Trial: NCT00463073
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00463073
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00463073
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01206387
Drug: Desoximetasone Spray 0.25%
DrugBank: Desoximetasone (DB00547)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
Trial: NCT00706849
Drug: mipomersen sodium
RxNorm normalized name: Mipomersen Sodium
DrugBank: Mipomersen (DB05528)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg /mL
Trial: NCT03476460
Drug: Oral sodium chloride
RxNorm normalized name: sodium chloride Oral Tablet
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive capsules of sodium chloride and free water ingestion (for each capsule of sodium chloride, with 250 ml of water, assuring a minimum ingestion of 750 ml of water) in the 48 hours prior contrast injection. Patients will take capsules of sodium chloride at a dose of 100 mg/kg during 48 hours previous the injection of contrast (48, 40, 32, 24, 16, and 8 hours), at the moment of contrast injection and 12 hours after the injection of contrast.
Trial: NCT01032759
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg, BID
Trial: NCT02294552
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02294552
Drug: Fludarabine monophosphate
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01343225
Drug: atripla
RxNorm normalized name: Atripla
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once a day
Trial: NCT01343225
Drug: darunavir ritonavir raltegravir
RxNorm normalized name: darunavir and ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: as directed
Trial: NCT03476460
Drug: Intravenous sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive at hospital 3 ml/Kg of sodium chloride 0.9%, one hour previous contrast injection and 2 ml/kg during the 4 hours after contrast injection.
Trial: NCT03713580
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adding Venetoclax, a BCL-2 inhibitor, to standard high dose therapy prior to autologous stem cell transplant (ASCT).~Venetoclax is a novel, orally bioavailable, small-molecule B-cell lymphoma-2 (Bcl-2) family inhibitor.
Trial: NCT02294552
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02294552
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01896700
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escalating dose of methylphenidate, 20mg, 40mg, 60mg/day, for 2 weeks each
Trial: NCT00886782
Drug: Cdc7-inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, QD x 14 days until MTD is reached, 14d per 28 day cycle/QD 12 months
Trial: NCT03269552
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02222155
Drug: CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02222155
Drug: CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00208546
Drug: 21Capecitabine + bevacizumab + oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1.
Trial: NCT00208546
Drug: 1Capecitabine + oxaliplatin + bevacizumab + cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1, Ce 250 mg/m2 i.v. day 1, 8, 15 (day 1 cycle 1: 400 mg/m2).
Trial: NCT01382511
Drug: Simvastatine
RxNorm normalized name: Simvastatine
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg
Trial: NCT04541251
Drug: Camrelizumab + Nab-paclitaxel + Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients will receive three cycles (one cycle is defined as every 21 days +/- 3 days) of neoadjuvant therapy with camrelizumab 200 mg, nab-paclitaxel 260 mg/m2, and carboplatin AUC 5. This will then be followed by surgery.
Trial: NCT04292223
Drug: Pimavanserin
RxNorm normalized name: Pimavanserin
DrugBank: Pimavanserin (DB05316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimavanserin 34 mg (provided as 1×34 mg capsule), administered orally, once daily for 16 weeks
Trial: NCT00981773
Drug: Maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maraviroc 150 mg bid
Trial: NCT00981773
Drug: Maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: maraviroc 150 mg bid switch 12 weeks later
Trial: NCT00531986
Drug: Lopinavir-Monotherapy
RxNorm normalized name: Lopinavir
DrugBank: Lopinavir (DB01601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients on triple HAART will be switched to LPV/r-monotherapy
Trial: NCT00003409
Drug: motexafin gadolinium
RxNorm normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006487
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During induction: 50 mg/m2/day, IV on Days 1, 8, 29, 36. 1 hour infusion~During consolidation: 60 mg/m2, IV on Day 1 only at approximately Week 11, Week 14. 1 hour infusion.
Trial: NCT00006487
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During induction: 50 mg/m2/day, IV on Days 1 - 5, 29 - 33. 1 hour infusion~During consolidation: 120 mg/m2, IV on Days 1, 2 and 3 at approximately Week 11, Week 14. 1 hour infusion.
Trial: NCT00006487
Drug: tirapazamine
RxNorm normalized name: Tirapazamine
DrugBank: Tirapazamine (DB04858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During induction:~Phase I low dose: 260 mg/m2/day, IV on Days 1, 8, 29, 36. 1 hour infusion~Phase II high dose: 330 mg/m2/day, IV on Days 1, 8, 29, 36 1 hour infusion~During consolidation:~330 mg/ m2, IV Day 1 only at approximately Week 11, Week 14. 1 hour infusion.
Trial: NCT00786851
Drug: Lenalidomide and Dexametasone
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide will be supplied as 5 mg and 25 mg capsules for oral administration.Dexamethasone (Soldesam 0.2%) will be supplied as 20 mg liquid for oral administration (1 bottle = 20 mg; daily dose = 2 bottles = 40 mg).
Trial: NCT04457466
Drug: Nerve Growth Factor
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction of experimental muscle soreness using intramuscular injections of Nerve Growth Factor.
Trial: NCT01475071
Drug: Metvix and conventional PDT
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methyl aminolevulinate, cream, 160mg/g. One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.
Trial: NCT02809261
Drug: 5% Dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% Dextrose could decrease the release of CGRP and substance P to reduce the nerve inflamation.
Trial: NCT01581944
Drug: 2 Doses Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3.6mg administered monthly for 2 months prior to myomectomy
Trial: NCT01581944
Drug: 3 Doses Goserelin
RxNorm normalized name: goserelin 3.6 MG
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3.6mg administered monthly for 3 months prior to myomectomy
Trial: NCT04039854
Drug: Isoflurane, Sevoflurane or Desflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The volatile anaesthetic agent will be administered via inhalation, i.e. ventilation through alveolar membrane in lungs) during the maintenance of anaesthesia. During CPB the volatile anaesthetic agent will be administered through the oxygenator oxygen inflow of the CPB machine.~The maintenance dose of the volatile anaesthetic agent will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia and blood pressure.~The administration of the volatile anaesthetic agent will be started after induction of anaesthesia and it will be ended at the end of surgery, before the patient is transferred to the CCU.
Trial: NCT04039854
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive propofol only during the surgical procedure. The maintenance dose of the propofol infusion will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia (titrated to a depth of anaesthesia with BIS 30-60) and mean arterial pressure (MAP) of 50-80mmHg by the treating anaesthetist.
Trial: NCT00369785
Drug: donepezil hydrochloride
RxNorm normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weeks 1-6: One tablet Donepezil 5 mg given daily Weeks 7-24: Two Donepezil 5 mg tablets given daily
Trial: NCT02345863
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Debulking:~2 cycles of Bendamustine (70 mg/m² iv) will be administered before induction unless a contraindication is existing or it is not clinically indicated.
Trial: NCT02345863
Drug: GA101
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction~GA101 iv infusion:~Cycle 1: Day 1 100 mg Day 1 (or 2) 900 mg Day 8 1000 mg Day 15 1000 mg Cycle 2-6: Day 1 1000 mg~Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.~GA101: Cycle 1-8 Day 1 1000 mg
Trial: NCT02345863
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib will be administered as a daily oral dosage of 420 mg starting on cycle 2 day 1.~Cycle 2-6: Day 1 420 mg daily~Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.~Ibrutinib: Cycle 1-8 420 mg daily
Trial: NCT03790007
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In our study this local anesthetic agent will be applied for postoperative pain relief
Trial: NCT03833947
Drug: lignocaine+bicarbonate
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETT cuff was filled with mixture of 2% lignocaine with bicarbonate
Trial: NCT03833947
Drug: lignocaine+dexamethasone
RxNorm normalized name: dexamethasone / lidocaine
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ETT cuff was filled with mixture of 2% lignocaine with dexamethasone
Trial: NCT00000318
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1. Experimental Maintenance treatment with daily medication~2. Experimental Maintenance treatment with thrice-weekly medication
Trial: NCT01602198
Drug: Exelon [rivastigmine] transdermal patch
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Exelon patch 1/day for six months
Trial: NCT00815516
Drug: micafungin
RxNorm normalized name: Micafungin
DrugBank: Micafungin (DB01141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered by intravenous infusion
Trial: NCT00815516
Drug: amphotericin B deoxycholate
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered by intravenous infusion
Trial: NCT01541345
Drug: InductOs
DrugBank: Dibotermin alfa (DB11639)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane). One time application at augmentation surgery.
Trial: NCT01077531
Drug: Otelixizumab
RxNorm normalized name: Otelixizumab
DrugBank: Otelixizumab (DB05496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otelixizumab injection for intravenous infusion. Otelixizumab (GSK2136525) is a humanised, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb).
Trial: NCT02438865
Drug: Immediate instillation of intravesical chemotherapy-Epirubicin-
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02438865
Drug: Maintainance therapy of intravesical chemotherapy-Epirubicin-
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no